Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCM

3' education - Apr. 2, 2022 - Prof. Milind Desai, MD - Cleveland, OH, USA

Educational information

This video was recorded at the Congress of the American College of Cardiology (ACC) 2022.

Faculty

Prof. Milind Desai, MD MBA, is the Director of Hypertrophic Cardiomyopathy Center and Clinical Operations at the Department of Cardiovascular Medicine in the Heart, Vascular & Thoracic Institute at Cleveland Clinic, Cleveland Ohio. He is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine.

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Read our summary of the VALOR-HCM trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.